Literature DB >> 25203674

A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.

Wiebke Hessenkemper1, Julia Roediger, Sophie Bartsch, Adriaan B Houtsmuller, Martin E van Royen, Iver Petersen, Marc-Oliver Grimm, Aria Baniahmad.   

Abstract

We have previously identified a natural occurring, androgen receptor-specific antagonist. Atraric acid (AA) inhibits the transactivation of the androgen receptor (AR) and androgen-mediated growth of AR-expressing human prostate cancer (PCa) cell lines. Here we show that AA treatment of living cells provokes molecular changes of AR signaling. In addition to a deceleration of nuclear translocation a block of the intramolecular amino/carboxy (N/C)-terminal interaction of the AR was observed. Furthermore, using high-resolution confocal fluorescence microscopy, a reduced speckle formation of the AR was observed in line with an increased intranuclear mobility of the receptor. This suggests decreased DNA binding of the AR, which is further indicated by an impaired chromatin recruitment of the AR to the prostate-specific antigen promoter and enhancer shown by chromatin immunoprecipitation experiments. Using inhibitors of the non-receptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence suggesting a partly non-genomic pathway to induce cellular senescence by AA. Using PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) pyrimidine or Akt inhibitors, inhibitors of the nonreceptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence, suggesting a partly nongenomic pathway to induce cellular senescence by AA. Treatment of LNCaP cells with AA is associated with hypophosphorylation of the retinoblastoma tumor suppressor and an increase of p16 expression, whereas the p53-p21 signaling pathway seems not be affected by AA treatment. Analyzing human PCa tissue samples treated with AA ex vivo also indicates an induction of cellular senescence associated with an increase of p16 expression but not p21. Taken together, these data indicate that AA exhibits novel features to inhibit AR amino/carboxy-terminal interaction, the AR-mediated nuclear activities and growth of PCa cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25203674      PMCID: PMC5414792          DOI: 10.1210/me.2014-1170

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  31 in total

Review 1.  Prostate cancer schemes for androgen escape.

Authors:  A O Brinkmann; J Trapman
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.

Authors:  Kazutaka Ushio; Tomio Hashimoto; Naomi Kitamura; Toshiaki Tanaka
Journal:  Mol Cancer Res       Date:  2009-06-30       Impact factor: 5.852

3.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

4.  Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Authors:  Antimo Migliaccio; Marina Di Domenico; Gabriella Castoria; Merlin Nanayakkara; Maria Lombardi; Antonietta de Falco; Antonio Bilancio; Lilian Varricchio; Alessandra Ciociola; Ferdinando Auricchio
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells.

Authors:  Viola Lorenz; Wiebke Hessenkemper; Julia Rödiger; Sergiy Kyrylenko; Florian Kraft; Aria Baniahmad
Journal:  Horm Mol Biol Clin Investig       Date:  2011-10-01

6.  PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a.

Authors:  Ni Zeng; Kai-Ting Yang; Jennifer-Ann Bayan; Lina He; Richa Aggarwal; Joseph W Stiles; Xiaogang Hou; Vivian Medina; Danny Abad; Beth M Palian; Ismail Al-Abdullah; Fouad Kandeel; Deborah L Johnson; Bangyan L Stiles
Journal:  Aging Cell       Date:  2013-08-06       Impact factor: 9.304

Review 7.  Androgen receptor-mediated gene repression.

Authors:  Andreas Grosse; Sophie Bartsch; Aria Baniahmad
Journal:  Mol Cell Endocrinol       Date:  2011-07-19       Impact factor: 4.102

Review 8.  Hallmarks of senescence in carcinogenesis and cancer therapy.

Authors:  Jerry W Shay; Igor B Roninson
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

9.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

10.  Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence.

Authors:  Masashi Narita; Sabrina Nũnez; Edith Heard; Masako Narita; Athena W Lin; Stephen A Hearn; David L Spector; Gregory J Hannon; Scott W Lowe
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

View more
  18 in total

1.  A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling.

Authors:  Mohsen Esmaeili; Thanakorn Pungsrinont; Andrea Schaefer; Aria Baniahmad
Journal:  J Mol Med (Berl)       Date:  2016-06-16       Impact factor: 4.599

Review 2.  Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.

Authors:  Aria Baniahmad
Journal:  J Mol Neurosci       Date:  2015-11-12       Impact factor: 3.444

3.  Overview on the complexity of androgen receptor-targeted therapy for prostate cancer.

Authors:  Ammad Ahmad Farooqi; Fazlul H Sarkar
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

Review 4.  Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.

Authors:  Marisa Cabeza; Araceli Sánchez-Márquez; Mariana Garrido; Aylín Silva; Eugene Bratoeff
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Compounds from Cynomorium songaricum with Estrogenic and Androgenic Activities Suppress the Oestrogen/Androgen-Induced BPH Process.

Authors:  Xueni Wang; Rui Tao; Jing Yang; Lin Miao; Yu Wang; Jose Edouard Munyangaju; Nuttapong Wichai; Hong Wang; Yan Zhu; Erwei Liu; Yanxu Chang; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-15       Impact factor: 2.629

Review 6.  A Review of the Potential of Phytochemicals from Prunus africana (Hook f.) Kalkman Stem Bark for Chemoprevention and Chemotherapy of Prostate Cancer.

Authors:  Richard Komakech; Youngmin Kang; Jun-Hwan Lee; Francis Omujal
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-13       Impact factor: 2.629

Review 7.  Food components and contaminants as (anti)androgenic molecules.

Authors:  Daniele Marcoccia; Marco Pellegrini; Marco Fiocchetti; Stefano Lorenzetti; Maria Marino
Journal:  Genes Nutr       Date:  2017-02-16       Impact factor: 5.523

8.  Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.

Authors:  Siddharth Gupta; Thanakorn Pungsrinont; Ondrej Ženata; Laura Neubert; Radim Vrzal; Aria Baniahmad
Journal:  Horm Cancer       Date:  2020-06-20       Impact factor: 3.869

9.  Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.

Authors:  Malika Franziska Sutter; Maren C C M Ertingshausen; Thanakorn Pungsrinont; Gopinath Lakshmana; Miriam Kokal; Amir Saeed Khan; Aria Baniahmad
Journal:  Cell Biosci       Date:  2020-04-25       Impact factor: 7.133

10.  The activation of OR51E1 causes growth suppression of human prostate cancer cells.

Authors:  Désirée Maßberg; Nikolina Jovancevic; Anne Offermann; Annika Simon; Aria Baniahmad; Sven Perner; Thanakorn Pungsrinont; Katarina Luko; Stathis Philippou; Burkhard Ubrig; Markus Heiland; Lea Weber; Janine Altmüller; Christian Becker; Günter Gisselmann; Lian Gelis; Hanns Hatt
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.